BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QLS5316 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QLS5316\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07358884-2694@assetmemo.bio
DTSTAMP:20261121T005427Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS5316: Phase 1 readout est. (NCT07358884)
DESCRIPTION:QLS5316\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: First i
 n Human Study of QLS5316 in Solid Tumors\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qls5316#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0735
 8884
URL:https://assetmemo.bio/drug/qls5316#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
